SCHEMBL2126994

SCHEMBL2126994

COC(=O)c1ccc(C#N)c(-c2ccccc2OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
PGR P06401 2/20 0.46
AR P10275 2/20 0.46
MAPT P10636 2/20 0.44
ALDH1A1 P00352 2/20 0.44
XDH P47989 1/20 0.43
PDK2 Q15119 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
ESR1 P03372 1/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
VDR P11473 1/20 0.43
RXRA P19793 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
ESR2 Q92731 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7575780 0.87 HSD17B2 (0.51) SMN1; SMN2PGRARMAPTALDH1A1
SCHEMBL18356498 0.86 MAPT (0.48) SMN1; SMN2PGRARMAPTALDH1A1
SCHEMBL8155327 0.82 PTGS2 (0.54) MAPTALDH1A1XDHPDK2KDM4E
SCHEMBL6535961 0.81 MAPT (0.57) SMN1; SMN2MAPTALDH1A1XDHPDK2
SCHEMBL105391 0.81 ALDH1A1 (0.59) SMN1; SMN2MAPTALDH1A1XDHKDM4E
SCHEMBL1756642 0.81 MAPT (0.57) SMN1; SMN2PGRARMAPTALDH1A1
SCHEMBL7576216 0.80 ALDH1A1 (0.47) MAPTALDH1A1XDHPDK2RAB9A
SCHEMBL8009071 0.79 MAPT (0.54) SMN1; SMN2PGRARMAPTALDH1A1
SCHEMBL12670746 0.78
SCHEMBL2772957 0.77 AKR1C3 (0.57) MAPTALDH1A1PDK2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424843-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2014-03-26 EP disclosed
EP-2424843-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2014-03-26 EP disclosed
US-8598217-B2 Imidazole derivatives and their use as modulators of cyclin dependent kinases ASTEX THERAPEUTICS LTD. (GB) 2013-12-03 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
WO-2010125402-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES CDK3, CCNI, CDK1 SMN1; SMN2 3630/4885PGR 444/4885AR 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.